Astrazeneca (AZN) Tax Provisions (2009 - 2026)

Astrazeneca's Tax Provisions history runs 18 years deep, the most recent figure standing at $291.0 million for Q2 2026.

• In Q2 2026, Tax Provisions fell 57.14% year-over-year to $291.0 million; the TTM figure through Jun 2026 stood at -$1.6 billion (down 327.27% YoY), while the FY2025 annual figure was $2.2 billion, up 31.45% from the prior year.
• Tax Provisions for Q2 2026 stood at $291.0 million, up from -$833.0 million in the prior quarter.
• The five-year high for Tax Provisions was $720.0 million in Q3 2022, with the low at -$1.0 billion in Q4 2023.
• The 5-year median for Tax Provisions is -$287.0 million (2023), against an average of -$233.9 million.
• The sharpest annual moves came in 2023 and 2025: Tax Provisions tumbled 906.45% in 2023, then surged 244.78% in 2025.
• Astrazeneca's Tax Provisions stood at $124.0 million in 2022, then sank by 906.45% to -$1.0 billion in 2023, then soared by 83.4% to -$166.0 million in 2024, then sank by 80.72% to -$300.0 million in 2025, then soared by 197.0% to $291.0 million in 2026.
• Business Quant data shows AZN's Tax Provisions at $291.0 million in Q2 2026, -$833.0 million in Q1 2026, and -$300.0 million in Q4 2025.